

3 April 2025

Argent BioPharma Ltd. (Argent BioPharma or the Company)

CannEpi[™] Receives Approval for Prescription in Germany

Highlights:

- **CannEpi[™] has been approved for prescription in Germany, marking a significant expansion in the European market.**
- **Physicians can now prescribe CannEpi[™], allowing eligible patients access through prescription pathways.**
- **Epilepsy in Germany: approximately 816,000 people affected¹, with a high demand for innovative treatment solutions.**
- **Milestone achievement: Strengthens Argent BioPharma's position in neuroimmune modulation and cannabinoid-based therapeutics.**

CannEpi[™] Gains Approval for Prescription in Germany

Argent BioPharma (ASX: RGT) is pleased to announce that CannEpi[™], its flagship cannabinoid-based therapy for refractory epilepsy, has been approved for prescription in Germany under special access scheme. This approval represents a major milestone in the company's European expansion strategy and reinforces its commitment to providing innovative treatments for central nervous system (**CNS**) disorders.

This achievement marks a significant step in Argent BioPharma's European expansion, strengthening its presence in Germany, a key pharmaceutical hub. Establishing a foothold in this market paves the way for broader penetration into other EU markets with similar regulatory pathways, facilitating wider adoption of Argent's therapies.

Beyond geographical growth, this milestone underscores the increasing acceptance of cannabinoid-based medicine for CNS disorders. It positions CannEpi[™] as an accessible treatment for refractory epilepsy, offering a vital alternative for patients with limited therapeutic options.

Strategically, this progress enhances Argent BioPharma's growth trajectory while reinforcing its leadership in neuroimmune modulation and CNS-focused therapeutics. Most importantly, it ensures life-changing treatment access for patients who need it most, aligning with the company's mission to innovate and expand the reach of cutting-edge medical solutions.


Physician Recommendations & Prescription Pathway:

- CannEpi[™] is now available for prescription by qualified physicians in Germany.
- Patients may be eligible for health insurance coverage depending on their physician's recommendation and case assessment.
- This approval significantly enhances access for patients with drug-resistant epilepsy.

Epilepsy in Germany:

- Approximately 816,000 people in Germany are diagnosed with epilepsy¹, with a substantial portion suffering from drug-resistant forms (PMC9480957).

¹ <https://pmc.ncbi.nlm.nih.gov/articles/PMC9480957/>



- Current treatment options remain limited, underscoring the critical need for novel therapeutic approaches.
- CannEpi™ offers a promising alternative to traditional treatments, leveraging cannabinoid-based neuroimmune modulation for seizure management.

Roby Zomer, Managing Director and CEO of Argent BioPharma, commented:

“The approval of CannEpi™ in Germany represents a significant milestone for Argent BioPharma and the patients who rely on innovative treatments for epilepsy. This marks our continued expansion in Europe and reinforces our commitment to improving lives through cutting-edge cannabinoid-based medicine.”

Next Steps

- Initiate physician education programs across Germany.
- Expand CannEpi™ distribution and accessibility through key German partners.
- Continue regulatory efforts to gain approval in additional EU markets.
- Monitor market uptake and patient outcomes to support ongoing research and development.

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma

Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (ASX: RGT) is an innovative clinical-stage biopharmaceutical company specializing in neuroimmunology and advanced nanomedicine. By leveraging the Neuro-Immune Modulatory (NIM) System, Argent BioPharma’s robust pipeline—including CannEpi®, CogniCann®, and CimetrA®—targets CNS disorders and immune-related conditions. With a commitment to science-driven innovation, Argent BioPharma is shaping the future of cannabinoid-based therapeutics and neuroimmune modulation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma



Argent BioPharma Ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 info@argentbiopharma.com